Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2020
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 23 Sep 2020 Results of pooled analysis of data pooled from 4 studies ( CADMUS, CADMUS-JR, LOTUS and PEARL) extrapolating pharmacodynamic effects of Ustekinumab from Adults to Pediatrics, presented at the 2020 American College of Clinical Pharmacology Annual Meeting
- 31 Aug 2020 Results of pooled analysis (of data from CADMUS, CADMUS JR, LOTUS and PEARL) extrapolating pharmacodynamic effects from adults to pediatrics published in the Clinical Pharmacology and Therapeutics
- 05 Mar 2012 Actual start date changed from Nov 2009 to Oct 2009 as reported by ClinicalTrials.gov.